Biochemical and immunological aspects of COVID-19 infection and therapeutical intervention of oral low dose cytokine therapy: a systematic review

References

• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574.
   PubMed Web of Science ®Google Scholar
• Juliet B, Delia E, Johan G, et al. COVID-19: towards controlling of a pandemic. Lancet. 2020;395(10229):1015–1018.
   PubMed Web of Science ®Google Scholar
• Ronconi G, Tete G, Kritas SK, et al. SARS-CoV-2, which induces COVID-19, causes kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines. J Biol Regul Homeost Agents. 2020;34(3):767–773.
   PubMed Web of Science ®Google Scholar
• Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents. 2020;34(2):339–343.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393.
   PubMed Web of Science ®Google Scholar
• Lissenberg A, Vrolijk MM, van Vliet AL, et al. Luxury at a cost? Recombinant mouse hepatitis viruses expressing the accessory hemagglutinin esterase protein display reduced fitness in vitro. J Virol. 2005;79(24):15054–15063.
   PubMed Web of Science ®Google Scholar
• Glowacka I, Bertram S, Muller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85(9):4122–4134.
   PubMed Web of Science ®Google Scholar
• Matsuyama S, Nagata N, Shirato K, et al. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010;84(24):12658–12664.
   PubMed Web of Science ®Google Scholar
• Shulla A, Heald-Sargent T, Subramanya G, et al. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol. 2011;85(2):873–882.
   PubMed Web of Science ®Google Scholar
• Li W, Moore MI, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–445.
   PubMed Web of Science ®Google Scholar
• Markus H, Hannah KW, Simon S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel Coronavirus from patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
   PubMed Web of Science ®Google Scholar
• Harmer D, Gilbert M, Borman R, et al. Quantitative mRNA expression profiling of ACE2, a novel homologue of angiotensin converting enzyme. FEBS Letter. 2002;532(1–2):107–110.
   PubMed Web of Science ®Google Scholar
• Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang M, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263.
   PubMed Web of Science ®Google Scholar
• Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.
   PubMed Web of Science ®Google Scholar
• Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36–49.
   PubMed Web of Science ®Google Scholar
• Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9.
   PubMed Web of Science ®Google Scholar
• Belz GT, Smith CM, Kleinert L, et al. Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus. Proc Natl Acad Sci U S A. 2004;101(23):8670–8675.
   PubMed Web of Science ®Google Scholar
• Larsson M, Messmer D, Somersan S, et al. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. J Immunol. 2000;165(3):1182–1190.
   PubMed Web of Science ®Google Scholar
• Norbury CC, Malide D, Gibbs JS, et al. Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo. Nat Immunol. 2002;3(3):265–271.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol. 2004;78(11):5535–5545.
   PubMed Web of Science ®Google Scholar
• Saha B, Jyothi Prasanna S, Chandrasekar B, et al. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine. 2010;50(1):1–14.
   PubMed Web of Science ®Google Scholar
• Roman E, Miller E, Harmsen A, et al. CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. J Exp Med. 2002;196(7):957–968.
   PubMed Web of Science ®Google Scholar
• Swain SL, Agrewala JN, Brown DM, et al. Regulation of memory CD4 T cells: generation, localization and persistence. Adv Exp Med Biol. 2002;512:113–120.
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768.
   PubMed Web of Science ®Google Scholar
• Li T, Qiu Z, Zhang L, et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J Infect Dis. 2004;189(4):648–651.
   PubMed Web of Science ®Google Scholar
• Cecere TE, Todd SM, Leroith T. Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it? Viruses. 2012;4(5):833–846.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–787.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7):490–500.
   PubMed Web of Science ®Google Scholar
• Brown DM, Dilzer AM, Meents DL, et al. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol. 2006;177(5):2888–2898.
   PubMed Web of Science ®Google Scholar
• Zhong W, Roberts AD, Woodland DL. Antibody-independent antiviral function of memory CD4+ T cells in vivo requires regulatory signals from CD8+ effector T cells. J Immunol. 2001;167(3):1379–1386.
   PubMed Web of Science ®Google Scholar
• Christensen JP, Doherty PC, Branum KC, et al. Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8(?) T-cell memory. J. Virol. 2000;74(24):11690–11696.
   PubMed Web of Science ®Google Scholar
• Eichelberger M, Allan W, Zijlstra M, et al. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp Med. 1991;174(4):875–880.
   PubMed Web of Science ®Google Scholar
• Yi Y, Lagniton PNP, Ye S, et al. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020;16(10):1753–1766.
   PubMed Web of Science ®Google Scholar
• Wong RS, Wu A, To KF, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ. 2003;326(7403):1358–1362.
   PubMed Web of Science ®Google Scholar
• Cui W, Fan Y, Wu W, et al. Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin Infect Dis. 2003;37(6):857–859.
   PubMed Web of Science ®Google Scholar
• Kritas SK, Ronconi G, Caraffa A, et al. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents. 2020;34(1):9–14.
   PubMed Web of Science ®Google Scholar
• Cron RQ, Chatham WW. The rheumatologist's role in COVID-19. J Rheumatol. 2020;47(5):639–642.
   PubMed Web of Science ®Google Scholar
• Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102–108.
   PubMed Web of Science ®Google Scholar
• Meduri GU, Kohler G, Headley S, et al. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest. 1995;108(5):1303–1314.
   PubMed Web of Science ®Google Scholar
• Conti P, Gallenga CE, Tete G, et al. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1. J Biol Regul Homeost Agents. 2020;34(2):333–338.
   PubMed Web of Science ®Google Scholar
• Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies . J Biol Regul Homeost Agents. 2020;34(2):327–331.
   PubMed Web of Science ®Google Scholar
• Jose RJ, Williams AE, Chambers RC. Proteinase-activated receptors in fibroproliferative lung disease. Thorax. 2014;69(2):190–192.
   PubMed Web of Science ®Google Scholar
• Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847.
   PubMed Web of Science ®Google Scholar
• Antoniak S, Owens AP, Baunacke M, et al. PAR-1 contributes to the innate immune response during viral infection. J Clin Invest. 2013;123(3):1310–1322.
   PubMed Web of Science ®Google Scholar
• Khoufache K, Berri F, Nacken W, et al. PAR1 contributes to influenza A virus pathogenicity in mice. J Clin Invest. 2013;123(1):206–214.
   PubMed Web of Science ®Google Scholar
• Jose R, Williams A, Sulikowski M, et al. Regulation of neutrophilic inflammation in lung injury induced by community-acquired pneumonia. Lancet. 2015;385(1):52.
   Google Scholar
• Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol. 2005;5(12):917–927.
   PubMed Web of Science ®Google Scholar
• De Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523–534.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–539.
   PubMed Web of Science ®Google Scholar
• Kindler E, Thiel V, Weber F. Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. Adv Virus Res. 2016;96:219–243.
   PubMed Web of Science ®Google Scholar
• Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study. Clin Infect Dis. 2020;70(9):1837–1844.
   PubMed Web of Science ®Google Scholar
• Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques . Nat Med. 2013;19(10):1313–1317.
   PubMed Web of Science ®Google Scholar
• Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090–1095.
   PubMed Web of Science ®Google Scholar
• Kishida Y, Imaizumi N, Tanimura H, et al. A protease inhibitor with induction therapy with natural interferon-beta in patients with HCV genotype 1b infection. IJMS. 2016;17(3):350–362.
   Google Scholar
• Lu Y, Peng J, Wang C, et al. IL-6 promoter functional polymorphism -572C/G affects spontaneous clearance of hepatitis B virus infection . Clin Lab. 2014;60(11):1903–1907.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Chaouat G, Leiserson WM, et al. Characterization of T-Cell-soluble factors modulating the expression of La and H-2-antigens on Balb/C Lymphoma-B cell-lines. Cell. Immunol. 1983;76(2):253–267.
   PubMed Web of Science ®Google Scholar
• Bukowski JF, Welsh RM. Interferon enhances the susceptibility of virus-infected fibroblasts to cytotoxic T cells . J Exp Med. 1985;161(1):257–262.
   PubMed Web of Science ®Google Scholar
• Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76(2):301–314.
   PubMed Web of Science ®Google Scholar
• Croft M. Activation of naive, memory and effector T cells. Curr Opin Immunol. 1994;6(3):431–437.
   PubMed Web of Science ®Google Scholar
• Stout RD. Macrophage activation by T-cells - cognate and noncognate signals. Curr Opin Immunol. 1993;5(3):398–403.
   PubMed Web of Science ®Google Scholar
• Czarniecki CW, Fennie CW, Powers DB, et al. Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons. J Virol. 1984;49(2):490–496.
   PubMed Web of Science ®Google Scholar
• Lotti T, Hercogova J, Fabrizi G. Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy. Expert Opin Pharmacother. 2015;16(16):2485–2496.
   PubMed Web of Science ®Google Scholar
• Cardani D, Dusio G, Luchini P, et al. Oral administration of interleukin-10 and anti-IL-1 antibody ameliorates experimental intestinal inflammation. Gastroenterology Res. 2013;6(4):124–133.
   PubMedGoogle Scholar
• Florence MR, Shahida B. Oral cytokine administration. Immunol Today. 1996;17:548–550. doi:.
   PubMedGoogle Scholar
• Martin-Martin LS, Giovannangeli F, Bizzi E, et al. An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis. Drug Des Devel Ther. 2017;11:985–994.
   PubMed Web of Science ®Google Scholar
• Lotti T, Rivkina T, Kadurina M. New winning strategies for vitiligo: the low dose cytokines therapy approach. J Pigment Disord. 2015;2:12.
   Google Scholar
• Gariboldi S, Palazzo M, Zanobbio L, et al. Low dose oral administration of cytokines for treatment of allergic asthma. Pulm Pharmacol Ther. 2009;22(6):497–510.
   PubMed Web of Science ®Google Scholar
• Platanias LC. Mechanisms of Type-I- and Type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375–386.
   PubMed Web of Science ®Google Scholar
• Billiau A, Matthys P. Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev. 2009;20(2):97–113.
   PubMed Web of Science ®Google Scholar
• DE Andrea M, Ravera R, Gioia D, et al. The interferon system: an overview. EJPN. 2002;6:A41–A46.
   PubMedGoogle Scholar
• Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. Philadelphia (PA): Elsevier Saunders; 2015.
   Google Scholar
• Haller O, Kochs G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology. 2006;344(1):119–130.
   PubMed Web of Science ®Google Scholar
• Ronnblom L. The importance of the type I interferon system in autoimmunity. Clin Exp Rheumatol. 2016;34(4):21–24.
   PubMed Web of Science ®Google Scholar
• Parham P, Janeway C. The immune system. London: Garland Science; 2009.
   Google Scholar
• Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005;23:275–306.
   PubMed Web of Science ®Google Scholar
• Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284(5421):1835–1837.
   PubMed Web of Science ®Google Scholar
• Michael G, Jr, Seng-Lai T, Michael GK. Translational control of viral gene expression in eukaryotes. Microbiol Mol Biol Rev. 2000;64(2):239–280.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Navajas JM, Lee J, David M, et al. Immunomodulatory functions of type I interferons. Nat Rev Immunol. 2012;12(2):125–135.
   PubMed Web of Science ®Google Scholar
• Stackaruk ML, Lee AJ, Ashkar AA. Type I interferon regulation of natural killer cell function in primary and secondary infections. Expert Rev Vaccines. 2013;12(8):875–884.
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–510.
   PubMed Web of Science ®Google Scholar
• Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163–189.
   PubMed Web of Science ®Google Scholar
• Green DS, Young HA, Valencia JC. Current prospects of type II interferon γ signaling and autoimmunity. J Biol Chem. 2017;292(34):13925–13933.
   PubMed Web of Science ®Google Scholar
• Andreakos E, Zanoni I, Galani IE. Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control. Curr Opin Immunol. 2019;56:67–75.
   PubMed Web of Science ®Google Scholar
• Lin FC, Young HA. Interferons: success in anti-viral immunotherapy. Cytokine Growth Factor Rev. 2014;25(4):369–376.
   PubMed Web of Science ®Google Scholar
• Rizza P, Capone I, Urbani F, et al. Evaluation of the effects of human leukocyte IFN-alpha on the immune response to the HBV vaccine in healthy unvaccinated individuals. Vaccine. 2008;26(8):1038–1049.
   PubMed Web of Science ®Google Scholar
• Sommereyns C, Paul S, Staeheli P, et al. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008;4(3):e1000017.
   PubMed Web of Science ®Google Scholar
• Robert MF. Antiviral activity of interferons. Bacteriol Rev. 1977;41(3):543–567.
   PubMedGoogle Scholar
• Akdis M, Burgler S, Crameri R, et al. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2011;127(3):701–721.
   PubMed Web of Science ®Google Scholar
• Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10(2):89–102.
   PubMed Web of Science ®Google Scholar
• Hsieh CS, Macatonia SE, Tripp CS, et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260(5107):547–551.
   PubMed Web of Science ®Google Scholar
• Chan SH, Perussia B, Gupta JW, et al. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers . J Exp Med. 1991;173(4):869–879.
   PubMed Web of Science ®Google Scholar
• Chehimi J, Valiante NM, D'Andrea A, et al. Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells. Eur J Immunol. 1993;23(8):1826–1830.
   PubMed Web of Science ®Google Scholar
• Schijns VE, Haagmans BL, Horzinek MC. IL-12 stimulates an antiviral type 1 cytokine response but lacks adjuvant activity in IFN-gamma-receptor-deficient mice. J Immunol. 1995;155(5):2525–2532.
   PubMed Web of Science ®Google Scholar
• Lenardo MJ. Fas and the art of lymphocyte maintenance. J Exp Med. 1996;183(3):721–724.
   PubMed Web of Science ®Google Scholar
• Marks-Konczalik J, Dubois S, Losi JM, et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice . Proc Natl Acad Sci U S A. 2000;97(21):11445–11450.
   PubMed Web of Science ®Google Scholar
• Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol. 2006;24:657–679.
   PubMed Web of Science ®Google Scholar